Claudio Osorio, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,145 of the $11,517 with a category attached, or 88.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 362 payments — averaging $31.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Livanova USA, Inc.$2K
- AbbVie$1K
- Eisai Inc.$834
- SK Life Science, Inc.$672
- Jazz Pharmaceuticals Inc.$654
- plus $4K from 27 others
What the payments were for
- Travel & lodging$1,37212%
- Food & beverage$10,14588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 48 | $1,974 |
| Livanova USA, Inc. | 14 | $1,927 |
| AbbVie(2 entities) | 69 | $1,406 |
| Eisai Inc. | 31 | $834 |
| SK Life Science, Inc. | 19 | $672 |
| Jazz Pharmaceuticals Inc. | 18 | $654 |
| Neurelis, Inc. | 27 | $534 |
| Lilly USA, LLC | 24 | $468 |
| Argenx US, Inc. | 9 | $452 |
| Pfizer | 9 | $328 |
| Biohaven Pharmaceuticals, Inc. | 18 | $296 |
| Teva Pharmaceuticals USA, Inc. | 3 | $273 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $218 |
| Amgen | 11 | $214 |
| Novartis | 6 | $130 |
| Sunovion Pharmaceuticals Inc. | 6 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $121 |
| Aquestive Therapeutics, Inc. | 7 | $117 |
| Smith+Nephew | 1 | $114 |
| Catalyst Pharmaceuticals, Inc. | 4 | $103 |
| GE HealthCare | 5 | $102 |
| Sumitomo Pharma America, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $70 |
| Lundbeck LLC | 2 | $50 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| Greenwich Biosciences, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| Aucta Pharmaceuticals, Inc. | 2 | $23 |
| AstraZeneca | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,632
- Fintepla$364
- Austedo XR$257
- Fycompa$245
- Epidiolex$233
- NURTEC ODT$125
- VYVGART$121
- REXULTI$121
- UBRELVY$116
- ACTICOAT 4" X 4"$114
- ALLEVYN HEEL 10.5CM X 13.5CM CTN 5$114
- Iodosorb Ointment 40g USA$114
- COLLAGENASE SANTYL$114
- Nayzilam$112
- VALTOCO$111
- XCOPRI$101
How this compares
$11,517 in reported general payments places this provider in the 60th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 46 | $1,422 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 29 | $1,234 |
| Gabapentin | 38 | $1,124 |
| Memantine Hcl | 28 | $679 |
| Donepezil Hcl | 60 | $470 |
| Galantamine Hbr | 19 | $438 |
| Topiramate | 17 | $110 |
| Lamotrigine | 14 | $105 |
| Rosuvastatin Calcium | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Tampa
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
- Brin FreundJacksonville$18K
- Miguel Melo-BicchiMiami$15K
- Carlos MillanMiami$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.